Zomedica Corp. (NYSEAMERICAN:ZOM) Director Acquires $112,500.00 in Stock

Zomedica Corp. (NYSEAMERICAN:ZOM) Director Johnny D. Powers bought 250,000 shares of Zomedica stock in a transaction on Thursday, November 18th. The shares were purchased at an average price of $0.45 per share, for a total transaction of $112,500.00. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.

Shares of ZOM opened at $0.44 on Thursday. Zomedica Corp. has a 52 week low of $0.12 and a 52 week high of $2.91. The company has a market capitalization of $426.65 million, a PE ratio of -7.26 and a beta of 0.47.

Several institutional investors and hedge funds have recently modified their holdings of the company. StoneX Group Inc. bought a new stake in shares of Zomedica in the 1st quarter worth approximately $32,000. Thrivent Financial for Lutherans bought a new stake in shares of Zomedica in the 1st quarter worth approximately $34,000. Royal Bank of Canada boosted its position in shares of Zomedica by 899.5% in the 1st quarter. Royal Bank of Canada now owns 26,577 shares of the company’s stock worth $42,000 after purchasing an additional 23,918 shares in the last quarter. Toroso Investments LLC boosted its position in shares of Zomedica by 23.7% in the 2nd quarter. Toroso Investments LLC now owns 139,745 shares of the company’s stock worth $116,000 after purchasing an additional 26,780 shares in the last quarter. Finally, Teacher Retirement System of Texas boosted its position in shares of Zomedica by 25.3% in the 3rd quarter. Teacher Retirement System of Texas now owns 144,694 shares of the company’s stock worth $76,000 after purchasing an additional 29,230 shares in the last quarter. 13.36% of the stock is currently owned by hedge funds and other institutional investors.

About Zomedica

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs.

Read More: How Investors Can Profit from Options Trading

Insider Buying and Selling by Quarter for Zomedica (NYSEAMERICAN:ZOM)

Receive News & Ratings for Zomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica and related companies with MarketBeat.com's FREE daily email newsletter.